Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced the appointment of Dave Goyette as Chief Technology Officer (CTO). Mr. Goyette brings more than 30 years of healthcare technology, software development, medical imaging, and gaming experience to Ehave.
As CTO, Mr. Goyette will lead the technological development of Ehave Connect, Ehave’s flagship informatics platform for the mental health industry. Ehave Connect empowers practitioners with a next generation of data-rich patient management, assessment, and remediation tools. Initially, Mr. Goyette will oversee the integration of third-party tools and content into Ehave Connect, including the Conners® suite of ADHD assessments developed by Ehave partner Multi-Health Systems. Mr. Goyette will also work with Ehave partner MedReleaf on the development of an Ehave Connect application to advance the study and therapeutic use of medical cannabis.
Prior to joining Ehave, Mr. Goyette, together with Ehave CEO Prateek Dwivedi, developed a Cancer Informatics Program at Princess Margaret Hospital at the University Health Network in Toronto. The Cancer Informatics Program unites information from various clinical systems to give users a holistic and objective view of patient health, treatment, and outcomes data.
“I’m excited to work with Dave again, this time to modernize the mental healthcare space,” said Mr. Dwivedi. “Dave and I previously worked together at Princess Margaret Hospital where we designed their Cancer Informatics Platform. Dave understands the challenges and complexity of designing systems that capture and facilitate the flow of patient information. As we develop Ehave Connect and integrate with third-party partners, I’m confident that Dave will provide the leadership to help ensure our success.”
Prior to Princess Margaret Hospital, Mr. Goyette designed and implemented console and analytic tools for Novadaq SPY fluorescence imaging platform. During his tenure at Novadaq, Mr. Goyette co-authored several patents for the SPY product. Before Novadaq, Mr. Goyette proposed a concept for a new MMOG game to the Montecito Picture Company, and partnered with them on developing the concept and building a prototype in cooperation with a team of artists and game developers.
Mr. Goyette’s additional healthcare experience includes working with both Philips and Hitachi Medical Systems on the architecture and design of MRI devices. Dave received his undergraduate degree in Mathematics (double honours in Computer Science and C&O) from the University of Waterloo.
Ehave is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf. Ehave is headquartered in Toronto’s Discovery District, a hub of healthcare, innovation, and technology in Toronto, Canada.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.